Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Leede Financial analyst D. Loe forecasts that the company will earn $1.10 per share for the year. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share.
Cipher Pharmaceuticals Stock Up 6.7 %
Shares of TSE CPH traded up C$0.82 during mid-day trading on Monday, hitting C$12.98. 31,972 shares of the stock traded hands, compared to its average volume of 36,103. The company has a market cap of C$233.03 million, a price-to-earnings ratio of 14.33 and a beta of 1.20. The stock has a fifty day moving average price of C$12.82 and a 200-day moving average price of C$14.34. Cipher Pharmaceuticals has a 52 week low of C$7.90 and a 52 week high of C$19.69. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00.
Insider Buying and Selling
In other news, Director Harold Morton Wolkin sold 3,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of C$13.49, for a total transaction of C$47,215.00. 42.00% of the stock is currently owned by company insiders.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Featured Stories
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
